<DOC>
	<DOCNO>NCT02685683</DOCNO>
	<brief_summary>This study design explore mechanism action mongersen ( GED-0301 ) 160 mg daily patient active Crohn 's Disease</brief_summary>
	<brief_title>Pharmacodynamic Study Mongersen Patients With Crohn 's Disease</brief_title>
	<detailed_description>Subjects screen provide 20 enrolled subject complete 12 week mongersen ( GED-0301 ) 160 mg daily ( QD ) treatment open-label therapy . The study consist 4 period : - Screening Period - 4 week - Induction Period - 12 week ( Week 0 Visit Week 12 Visit ) Maintenance Period - 88 week ( Week 12 Visit Week - 100 Visit ) - Follow-up Period - 4 week ( ie , Investigational Product ( IP ) take Subjects prematurely discontinue treatment study prior Week 100 Early Termination Visit also enter 4-week Follow-up Period . At Screening Visit , subject meet entrance criterion eligible enter study . The number subject previous exposure Tumor Necrosis Factor-Alpha ( TNF-α ) blocker target approximately 40 % ( ie , approximately86 subject )</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female ≥ 18 year age . Active Crohn 's disease ( CD ) disease determine Crohn 's Disease Activity Index ( CDAI ) score Simple Endoscopic Score Crohn 's Disease ( SESCD ) Must meet determine average minimum number daily stool rating abdominal pain 7 day period Subject must fail experienced intolerance least one following : aminosalicylates ; budesonide ; systemic corticosteroid ; immunosuppressant ( eg , azathiopurine , 6mercaptopurine , methotrexate ) ; biologics treatment CD . Subject must use protocol approve contraception Diagnosis ulcerative colitis ( UC ) , indeterminate colitis , ischemic colitis , microscopic colitis , radiation colitis diverticular diseaseassociated colitis Local manifestation Crohn 's Disease ( CD ) symptomatic stricture , abscess , short bowel syndrome ; disease complication surgery might indicate could confound evaluation efficacy Intestinal resection within 6 month intraabdominal surgery within 3 month prior Screening Visit Ileostomy colostomy Prior treatment 2 TNFα blocker ( eg , infliximab adalimumab ) . Prior treatment integrin antagonist ( eg , natalizumab vedolizumab ) . Subject pregnant breastfeeding . Subject receive prior treatment mongersen ( GED0301 ) , participation clinical study involve mongersen ( GED0301 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>GED-0301</keyword>
	<keyword>Open-label</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Mongersen</keyword>
</DOC>